Journal
EXPERT REVIEW OF VACCINES
Volume 13, Issue 8, Pages 1027-1038Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1586/14760584.2014.935767
Keywords
dose schedule; dosing; HPV vaccination; immunogenicity; virus-like particle
Categories
Funding
- National Cancer Institute at the National Institutes of Health [R25T CA147832]
Ask authors/readers for more resources
HPV vaccines can prevent multiple cancers in women and men. Difficulties in the cost and completion of the three-dose vaccine series have led to considerations of alternative dose schedules. In clinical trials, three doses given within a 12-month period versus the standard 6-month period yielded comparable results, and immunogenicity appears comparable with two doses in adolescent females compared to the three-dose series in adult females. While the data are generally supportive of moving to a two-dose vaccine schedule among young female adolescents, the adoption of a two-dose vaccine schedule still poses a potential risk to the strength and longevity of the immune response. Public health authorities implementing a two-dose vaccine schedule should devise risk management strategies to minimize the potential impact on cancer prevention.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available